Hemasundara Reddy Lanka Reviewer
04 Apr 2025 09:16 PM

This paper presents a well-researched and timely contribution that addresses the intersection of data management, machine learning, and big data analytics within the pharmaceutical industry. It introduces a Pharmaceutical Data Management (PDM) Framework designed to improve decision-making across drug discovery, clinical trials, supply chain management, and regulatory compliance. The integration of both structured and unstructured data sources, combined with machine learning and NLP applications, reflects a thorough and multidimensional approach. The practical relevance is underscored by data from leading Indian pharmaceutical firms and reinforced through clear metrics on performance improvement.
While the paper demonstrates strong conceptual foundations and empirical depth, a few enhancements would increase its impact, rigor, and clarity.
Framework Clarity & Architecture
- The proposed PDM Framework is a core contribution but lacks visual representation or a modular breakdown of its components. A diagram or layered architecture model would help readers grasp how data governance, analytics, and compliance interact within the system.
Evaluation Methodology
- The pilot implementations and improvements (e.g., 19% increase in audit scores, 22% reduction in data retrieval time) are impressive, but the evaluation methodology should be described in more detail. What metrics were used? Were these improvements statistically validated?
Integration Challenges
- While challenges such as data silos and legacy systems are noted, the mitigation strategies remain abstract. Include concrete approaches (e.g., use of middleware, API layers, data lakes) to address these challenges in practice.
Model Interpretability
- Machine learning models such as Random Forests and Gradient Boosting are used, yet their interpretability in regulatory contexts is not discussed. Given the industry's focus on explain ability (especially in clinical and compliance contexts), it would be valuable to touch upon how model outputs are interpreted or audited.
Generalizability
- The study draws from the Indian pharmaceutical sector. Clarify how generalizable the findings and proposed framework are for global pharma companies, considering different regulatory regimes (e.g., EMA, FDA vs. CDSCO) and infrastructure maturity levels.
Hemasundara Reddy Lanka Reviewer
04 Apr 2025 09:14 PM